表4：异基因造血干细胞移植后t(8;21)急性髓系白血病患者微小残留病的抢先免疫治疗

数据集获取（Figshare）

• 源站标题：Table_4_Preemptive Immunotherapy for Minimal Residual Disease in Patients With t(8;21) Acute Myeloid Leukemia After Allogeneic Hematopoietic Stem Cell Transplantation.docx
• DOI：10.3389/fonc.2021.773394.s006
• 发布日期：2022-01-06
• 文件数：1 个
• 文件总体积：13.06 KB
• 源站页面：https://frontiersin.figshare.com/articles/dataset/Table_4_Preemptive_Immunotherapy_for_Minimal_Residual_Disease_in_Patients_With_t_8_21_Acute_Myeloid_Leukemia_After_Allogeneic_Hematopoietic_Stem_Cell_Transplantation_docx/17912882

命令行下载

curl -L -o "Table_4_Preemptive Immunotherapy for Minimal Residual Disease in Patients With t(8;21) Acute Myeloid Leukemia After Allogeneic Hematopoietic Stem Cell.docx" "https://ndownloader.figshare.com/files/32631575"

文件清单

• Table_4_Preemptive Immunotherapy for Minimal Residual Disease in Patients With t(8;21) Acute Myeloid Leukemia After Allogeneic Hematopoietic Stem Cell.docx（13.06 KB）

文件总体积 13.06 KB（源站 API 实测）。

数据说明

In patients with t(8;21) acute myeloid leukemia (AML), recurrent minimal residual disease (MRD) measured by RUNX1-RUNX1T1 transcript levels can predict relapse after allogeneic hematopoietic stem cell transplantation (allo-HSCT). This study aimed to compare the efficacy of preemptive interferon (IFN)-α therapy and donor lymphocyte infusion (DLI) in patients with t(8;21) AML following allo-HSCT. We also evaluated the appropriate method for patients with different levels of RUNX1-RUNX1T1 transcripts. In this retrospective study, consecutive patients who had high-risk t(8;21) AML and received allo-HSCT were enrolled. The inclusion criteria were as follows: (1) age ≤65 years; (2) regained MRD positive following allo-HSCT. MRD positive was defined as the loss of a ≥4.5-log reduction and/or <4.5-log reduction in the RUNX1-RUNX1T1 transcripts, and high-level, intermediate-level, and low-level MRDs were, respectively, defined as <2.5-log, 2.5−3.5-log, and 3.5−4.5-log reductions in the transcripts compared with the pretreatment baseline level. Patients with positive RUNX1-RUNX1T1 could receive preemptive IFN-α therapy or DLI, which was primarily based on donor availability and the intentions of physicians and patients. The patients received recombinant human IFN-α-2b therapy by subcutaneous injection twice a week every 4 weeks. IFN-α therapy was scheduled for six cycles or until the RUNX1-RUNX1T1 transcripts were negative for at least two consecutive tests. The rates of MRD turning negative for patients with low-level, intermediate-level, and high-level RUNX1-RUNX1T1 receiving IFN-α were 87.5%, 58.1%, and 22.2%, respectively; meanwhile, for patients with intermediate-level and high-level RUNX1-RUNX1T1 receiving DLI, the rates were 50.0% and 14.3%, respectively. For patients with low-level and intermediate-level RUNX1-RUNX1T1, the probability of overall survival at 2 years was higher in the IFN-α group than in the DLI group (87.6% vs. 55.6%; p = 0.003). For patients with high levels of RUNX1-RUNX1T1, the probability of overall survival was comparable between the IFN-α and DLI groups (53.3% vs. 83.3%; p = 0.780). Therefore, patients with low-level and intermediate-level RU

许可

CC BY 4.0

引用

学术使用请引用 DOI 10.3389/fonc.2021.773394.s006（source: https://frontiersin.figshare.com/articles/dataset/Table_4_Preemptive_Immunotherapy_for_Minimal_Residual_Disease_in_Patients_With_t_8_21_Acute_Myeloid_Leukemia_After_Allogeneic_Hematopoietic_Stem_Cell_Transplantation_docx/17912882）。